Trial Outcomes & Findings for Implementation of Genomics in Substance Use Disorder Treatment (NCT NCT04768114)

Last Updated: 2024-01-03

Results Overview

Participants in both groups were asked about their use of several smoking cessation medications (Question: "In the past 30 days, have you used any of the following prescription medications or over-the-counter aids to help you quit or cut back on smoking?"; Response options: 1=Bupropion or Zyban; 2=Varenicline or Chantix; 3=Nicotine patch; 4=Nicotine gum or lozenge; 5=Other (Specify).

Recruitment status

COMPLETED

Study phase

Target enrollment

148 participants

Primary outcome timeframe

Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Results posted on

2024-01-03

Participant Flow

The study opened to participant enrollment on 02/08/2021 and closed to participant enrollment on 05/29/2022.

Participant milestones

Participant milestones
Measure	Genetically-Informed RiskProfile Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Overall Study STARTED	74	74
Overall Study COMPLETED	69	63
Overall Study NOT COMPLETED	5	11

Reasons for withdrawal

Reasons for withdrawal
Measure	Genetically-Informed RiskProfile Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Overall Study Lost to Follow-up	5	10
Overall Study Withdrawal by Subject	0	1

Baseline Characteristics

Implementation of Genomics in Substance Use Disorder Treatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.	Total n=148 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	68 Participants n=5 Participants	62 Participants n=7 Participants	130 Participants n=5 Participants
Age, Categorical >=65 years	6 Participants n=5 Participants	12 Participants n=7 Participants	18 Participants n=5 Participants
Sex/Gender, Customized Female	51 Participants n=5 Participants	54 Participants n=7 Participants	105 Participants n=5 Participants
Sex/Gender, Customized Male	21 Participants n=5 Participants	19 Participants n=7 Participants	40 Participants n=5 Participants
Sex/Gender, Customized Trans female / trans w	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Sex/Gender, Customized Non-binary	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	73 Participants n=5 Participants	74 Participants n=7 Participants	147 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	27 Participants n=5 Participants	25 Participants n=7 Participants	52 Participants n=5 Participants
Race (NIH/OMB) White	45 Participants n=5 Participants	45 Participants n=7 Participants	90 Participants n=5 Participants
Race (NIH/OMB) More than one race	1 Participants n=5 Participants	4 Participants n=7 Participants	5 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Region of Enrollment United States	74 participants n=5 Participants	74 participants n=7 Participants	148 participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Population: Some participants did not complete assessments at prior to intervention, 30-day follow-up and 6 month follow-up so that is why the number of participants analyzed at these time points does not match the number of participants enrolled.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days Self-reported use of any smoking cessation medications at baseline	11 Participants	9 Participants
Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days Self-reported use of any smoking cessation medications at prior to intervention	9 Participants	2 Participants
Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days Self-reported use of any smoking cessation medications at 30-day follow-up	16 Participants	8 Participants
Change in Use of Smoking Cessation Pharmacotherapy in Past 30 Days Self-reported use of any smoking cessation medications at 6-month follow-up	15 Participants	8 Participants

PRIMARY outcome

Timeframe: Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Participants in both groups were asked "In the past 30 days, how many days did you smoke cigarettes" and "On the days in which you smoked cigarettes in the past month, about how many cigarettes did you smoke". The values from these questions are multiplied together and then divided by 30 (days) to calculate the number of cigarettes smoked per day for each participant.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Number of Cigarettes Smoked Per Day Self-reported cigarettes per day at baseline	13.1 cigarettes smoked per day Standard Deviation 8.2	12.3 cigarettes smoked per day Standard Deviation 7.7
Change in Number of Cigarettes Smoked Per Day Self-reported cigarettes per day at prior to intervention	12.0 cigarettes smoked per day Standard Deviation 8.5	11.5 cigarettes smoked per day Standard Deviation 7.5
Change in Number of Cigarettes Smoked Per Day Self-reported cigarettes per day at 30-day follow-up	9.2 cigarettes smoked per day Standard Deviation 8.4	9.7 cigarettes smoked per day Standard Deviation 7.5
Change in Number of Cigarettes Smoked Per Day Self-reported cigarettes per day at 6-month follow-up	7.3 cigarettes smoked per day Standard Deviation 7.3	9.1 cigarettes smoked per day Standard Deviation 8.1

SECONDARY outcome

Timeframe: Baseline, immediately prior to intervention receipt, 30-day follow-up, and 6-month follow-up

Participants in both groups were assessed on self-reported stage of readiness to quit smoking. This measure includes one item based on the Transtheoretical Model of Change and measured along stages of Precontemplation, Contemplation, Preparation, and Action. (Question: ""Are you thinking of quitting smoking?""; Response options: 1=No, I am not seriously considering quitting within the next 6 months (Precontemplation); 2=Yes, I am seriously considering quitting within the next 6 months (Contemplation); 3=Yes, I am seriously planning to quit within the next 30 days (Preparation); 4=I have quit smoking within the past 6 months (Action). A higher score represents a higher stage of readiness to quit smoking. "

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Readiness to Quit Smoking Baseline, Precontemplation count	16 Participants	22 Participants
Change in Readiness to Quit Smoking Baseline, Contemplation count	45 Participants	37 Participants
Change in Readiness to Quit Smoking Baseline, Preparation count	13 Participants	15 Participants
Change in Readiness to Quit Smoking Baseline, Action count	0 Participants	0 Participants
Change in Readiness to Quit Smoking Prior to intervention, Precontemplation count	12 Participants	13 Participants
Change in Readiness to Quit Smoking Prior to intervention, Contemplation count	41 Participants	39 Participants
Change in Readiness to Quit Smoking Prior to intervention, Preparation count	17 Participants	13 Participants
Change in Readiness to Quit Smoking Prior to intervention, Action count	1 Participants	1 Participants
Change in Readiness to Quit Smoking 30-day follow-up, Precontemplation count	8 Participants	12 Participants
Change in Readiness to Quit Smoking 30-day follow-up, Contemplation count	37 Participants	36 Participants
Change in Readiness to Quit Smoking 30-day follow-up, Preparation count	22 Participants	13 Participants
Change in Readiness to Quit Smoking 30-day follow-up, Action count	4 Participants	4 Participants
Change in Readiness to Quit Smoking 6-month follow-up, Precontemplation count	13 Participants	4 Participants
Change in Readiness to Quit Smoking 6-month follow-up, Contemplation count	29 Participants	43 Participants
Change in Readiness to Quit Smoking 6-month follow-up, Preparation count	16 Participants	9 Participants
Change in Readiness to Quit Smoking 6-month follow-up, Action count	10 Participants	7 Participants

SECONDARY outcome

Timeframe: Baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up

Population: Some participants did not complete assessments at baseline, immediately following intervention, 30-day follow-up and 6 month follow-up so that is why the number of participants analyzed at these time points does not match the number of participants enrolled.

Participants in both groups were assessed on self-reported perceptions of personal susceptibility to smoking-related diseases. This measure includes one item comprising the perceived susceptibility scale (Question: "How likely is it for you to develop a smoking-related disease such as lung cancer or chronic obstructive pulmonary disease (COPD), if you continue to smoke?"; Response options: 1=Very unlikely; 2=Somewhat unlikely; 3=Neither unlikely nor likely; 4=Somewhat likely; 5=Very likely). A higher score represents a higher perceived disease risk.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=72 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=72 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Perceived Disease Risk Baseline	4.5 score on a scale Standard Deviation 0.8	4.3 score on a scale Standard Deviation 0.8
Change in Perceived Disease Risk Immediately following intervention receipt	4.7 score on a scale Standard Deviation 0.7	4.3 score on a scale Standard Deviation 1.0
Change in Perceived Disease Risk 30-day follow-up	4.6 score on a scale Standard Deviation 0.6	4.4 score on a scale Standard Deviation 0.8
Change in Perceived Disease Risk 6-month follow-up	4.6 score on a scale Standard Deviation 0.8	4.5 score on a scale Standard Deviation 0.8

SECONDARY outcome

Timeframe: Baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up

Participants in both groups were assessed on self-reported perceptions of personal health benefits related to quitting smoking. This measure is based on 3 items from the Perceived Risks and Benefits Questionnaire (PRBQ) addressing benefits related to reduced risks of smoking-related diseases, avoidance of future health problems, and increased longevity if the participant were to quit smoking. Response options to individual items were assessed on a 5-point Likert-type scale ranging from 1=Very Unlikely to 5=Very Likely. Individual scores on the 3 items were then averaged together for a total scale range of 1 to 5. A higher score represents higher perceived benefits of cessation.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=73 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Perceived Benefits of Cessation Self-reported perception of benefits of cessation at baseline	4.2 score on a scale Standard Deviation 0.8	4.2 score on a scale Standard Deviation 0.8
Change in Perceived Benefits of Cessation Self-reported perception of benefits of cessation immediately following intervention receipt	4.2 score on a scale Standard Deviation 1.0	4.2 score on a scale Standard Deviation 0.8
Change in Perceived Benefits of Cessation Self-reported perception of benefits of cessation at 30-day follow-up	4.6 score on a scale Standard Deviation 0.7	4.4 score on a scale Standard Deviation 0.7
Change in Perceived Benefits of Cessation Self-reported perception of benefits of cessation at 6-month follow-up	4.6 score on a scale Standard Deviation 0.6	4.4 score on a scale Standard Deviation 0.7

SECONDARY outcome

Timeframe: Baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up

Population: Some participants did not complete assessments at immediately following intervention, 30-day follow-up and 6 month follow-up so that is why the number of participants analyzed at these time points does not match the number of participants enrolled.

Participants in both groups were assessed on self-reported perceptions of the importance of using smoking cessation medications to help quit smoking. This measure includes 4 items modified from the Beliefs and Attitudes about Buproprion Scale which assesses perceived importance of using medications for smoking cessation, perceived confidence in medications as a smoking cessation aid, general expectancy that smoking cessation medications help people stop smoking, and perceived confidence in being able to use smoking cessation medications within the next month. Response options to individual items were assessed on a 5-point Likert-type scale ranging from 1=Not at all to 5=Extremely. Individual scores on the 4 items were then averaged together for at total scale range of 1-5. A higher score represents a higher perceived value of cessation treatment.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Perceived Value of Cessation Treatments Baseline	3.0 score on a scale Standard Deviation 0.9	3.0 score on a scale Standard Deviation 0.9
Change in Perceived Value of Cessation Treatments Immediately following intervention receipt	3.3 score on a scale Standard Deviation 0.9	2.9 score on a scale Standard Deviation 0.8
Change in Perceived Value of Cessation Treatments 30-day follow-up	3.2 score on a scale Standard Deviation 1.0	2.9 score on a scale Standard Deviation 0.9
Change in Perceived Value of Cessation Treatments 6-month follow-up	3.0 score on a scale Standard Deviation 1.1	2.8 score on a scale Standard Deviation 1.0

SECONDARY outcome

Timeframe: Baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up

Participants in both groups were assessed on self-reported perceptions of personal ability to engage in activities that promote smoking cessation. This measure is based on 3 items modified from the Skill Self-Efficacy Scale and 3 items modified from the Try Self-Efficacy Scale. Skill self-efficacy items address confidence to solicit social support, avoid situations with a high risk of relapse, and distract oneself when experiencing cravings during a quit attempt. Try self-efficacy items address perceived personal ability to smoke fewer cigarettes a day, resist smoking for one week, and resist smoking for one month. Response options to individual items were assessed on a 5-point Likert-type scale ranging from 1=Not at all to 5=Very. Individual scores on the 3 items were then averaged together for a total scale range of 1-5. A higher score represents a higher perceived self-efficacy of cessation.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=74 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Change in Self-efficacy of Cessation Self-reported skill self-efficacy at baseline	3.5 score on a scale Standard Deviation 0.9	3.5 score on a scale Standard Deviation 0.8
Change in Self-efficacy of Cessation Self-reported skill self-efficacy immediately following intervention receipt	3.6 score on a scale Standard Deviation 0.7	3.7 score on a scale Standard Deviation 0.7
Change in Self-efficacy of Cessation Self-reported skill self-efficacy at 30-day follow-up	3.8 score on a scale Standard Deviation 1.0	3.9 score on a scale Standard Deviation 0.8
Change in Self-efficacy of Cessation Self-reported skill self-efficacy at 6-month follow-up	3.9 score on a scale Standard Deviation 1.0	3.9 score on a scale Standard Deviation 0.9
Change in Self-efficacy of Cessation Self-reported try self-efficacy at baseline	2.6 score on a scale Standard Deviation 1.0	2.6 score on a scale Standard Deviation 1.0
Change in Self-efficacy of Cessation Self-reported try self-efficacy immediately following intervention receipt	2.6 score on a scale Standard Deviation 1.0	2.6 score on a scale Standard Deviation 1.0
Change in Self-efficacy of Cessation Self-reported try self-efficacy at 30-day follow-up	2.8 score on a scale Standard Deviation 1.2	3.0 score on a scale Standard Deviation 1.1
Change in Self-efficacy of Cessation Self-reported try self-efficacy at 6-month follow-up	3.2 score on a scale Standard Deviation 1.4	3.4 score on a scale Standard Deviation 1.2

SECONDARY outcome

Timeframe: Immediately following intervention receipt

Population: Some participants did not complete the assessment immediately following intervention so that is why the number of participants analyzed does not match the number of participants enrolled.

Participants in both groups were assessed on self-reported perceptions of the extent to which the intervention was personally significant and applicable. This measure includes 4 items modified from the Personal Relevance Scale and addresses the extent to which the intervention helped participants learn something about themselves, the role that their personal characteristics play in their smoking, how smoking affects their life, and the impact on their smoking cessation attempts. Response options to individual items were assessed on a 5-point Likert-type scale ranging from 1=Strongly Disagree to 5=Strongly Agree. Individual scores on the 4 items were then averaged together for a total scale range of 1 to 5. A higher score represents a higher perception of personal relevance of the intervention.

Outcome measures

Outcome measures
Measure	Genetically-Informed RiskProfile n=72 Participants Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=66 Participants Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Personal Relevance of Intervention	4.5 score on a scale Standard Deviation 0.6	3.7 score on a scale Standard Deviation 0.8

Adverse Events

Genetically-Informed RiskProfile

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Brief Cessation Advice

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Genetically-Informed RiskProfile n=74 participants at risk Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change. This is a fully remote trial, with intervention delivered via video conferencing.	Brief Cessation Advice n=74 participants at risk Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed. This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Psychiatric disorders Anxiety	1.4% 1/74 • Adverse events were collected at baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up. Adverse events were collected when self-reported by participants during the trial.	0.00% 0/74 • Adverse events were collected at baseline, immediately following intervention receipt, 30-day follow-up, and 6-month follow-up. Adverse events were collected when self-reported by participants during the trial.

Additional Information

Alex T. Ramsey, Ph.D.

Washington University School of Medicine

Phone: 314-362-5370

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place